355 related articles for article (PubMed ID: 9131254)
1. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic drug metabolism.
Relling MV
Clin Pharm; 1989 Dec; 8(12):852-63. PubMed ID: 2689060
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM; Skoda RC; Grant D; Blum M
Prog Liver Dis; 1990; 9():307-23. PubMed ID: 2156298
[No Abstract] [Full Text] [Related]
4. Polymorphic drug oxidation in humans.
Eichelbaum M
Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
[TBL] [Abstract][Full Text] [Related]
5. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of drug metabolism.
Meyer UA
Fundam Clin Pharmacol; 1990; 4(6):595-615. PubMed ID: 1982880
[TBL] [Abstract][Full Text] [Related]
8. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
9. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
10. [Interindividual differences in the reaction to drugs and poisons].
Meyer UA
Ther Umsch; 1992 Feb; 49(2):97-101. PubMed ID: 1553631
[TBL] [Abstract][Full Text] [Related]
11. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
[TBL] [Abstract][Full Text] [Related]
12. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
13. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
14. Populations and genetic polymorphisms.
Weber WW
Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
16. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population.
Torkaman-Boutorabi A; Hoormand M; Naghdi N; Bakhshayesh M; Milanian I
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1207-11. PubMed ID: 17880378
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
18. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
19. Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population.
Martínez C; Agúndez JA; Olivera M; Llerena A; Ramirez R; Hernández M; Benítez J
Clin Pharmacol Ther; 1998 Jun; 63(6):623-8. PubMed ID: 9663176
[TBL] [Abstract][Full Text] [Related]
20. [Knowledge about metabolic capacity is important in drug therapy].
Alván G; Dahl ML
Lakartidningen; 1992 Feb; 89(6):382, 387-90. PubMed ID: 1738265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
